Erin Schenk

Assistant Professor

University of Colorado Anschutz Medical Campus

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Erin Schenk is an Assistant Professor at the University of Colorado at Denver - Anschutz Medical Campus. Her research focuses on the therapeutic potential of targeting various pathways in lung cancer, particularly through studies on immune signaling and treatment responses. Recent articles authored by Dr. Schenk examine innovative strategies for cancer treatment and the implications of biomarkers in predicting patient outcomes.

Articles (10)

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Rafael Gómez-Sjöberg

Chief Technology Officer

UNITED STATES

View details

Jeff Kwak

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

WEI WU

University of California, San Francisco

UNITED STATES

View details

Rachael Kaspar

University of Minnesota

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Erin Schenk

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

2020 Innovation-Based Optimism for Lung Cancer Outcomes

CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC

Cancer Cell-Specific Major Histocompatibility Complex II Expression as a Determinant of the Immune Infiltrate Organization and Function in the NSCLC Tumor Microenvironment

Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation

Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma.

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study

Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer

Safety of influenza vaccine in patients with cancer receiving pembrolizumab

Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing

Collaborators (4)

Rafael Gómez-Sjöberg

Jeff Kwak

WEI WU

Rachael Kaspar

Make your next move.